Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Acurx Pharmaceuticals, Inc. (ACXP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"CONDENSED INTERIM BALANCE SHEETS June 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash $ 9,145,835 $ 9,111,751 Prepaid Expenses 89,942 264,955 TOTAL ASSETS $ 9,235,777 $ 9,376,706 LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES Accounts Payable and Accrued Expenses $ 3,019,408 $ 2,061,685 TOTAL CURRENT LIABILITIES 3,019,408 2,061,685 TOTAL LIABILITIES 3,019,408 2,061,685 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY Common Stock; $.001 par value, 200,000,000 shares authorized, 13,005,128 and 11,627,609 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 13,005 11,628 Additional Paid-In Capital 51,192,646 45,944,478 Accumulated Deficit TOTAL SHAREHOLDERS’ EQUITY 6,216,369 7,315,021 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 9,235,777 $ 9..." |
|
| 05/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"Agreement”) constitutes the agreement between Maxim Group LLC and Acurx Pharmaceuticals, Inc., a Delaware corporation , that the Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement of the Company’ s shares of Common Stock, par value $0.001 per share, , pre-funded warrants to purchase shares of Common Stock , Series C warrants to purchase shares of Common Stock and Series D warrants to purchase shares of Common Stock (the “Series D Warrants”, collectively with the Series C Warrants, the “Warrants",
"SERIES C COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: _______ Initial Exercise Date: November 18, 2023 Issue Date: May 18, 2023 THIS SERIES C COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or November 18, 2023 and on or prior to 5:00 p.m. on November 18, 2025 , but not thereafter, to subscribe for and purchase from Acurx Pharmaceuticals, Inc., a Delaware corporation , up to _______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not oth...",
"SERIES D COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: _______ Initial Exercise Date: November 18, 2023 Issue Date: May 18, 2023 THIS SERIES D COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or November 18, 2023 and on or prior to 5:00 p.m. on November 19, 2029 , but not thereafter, to subscribe for and purchase from Acurx Pharmaceuticals, Inc., a Delaware corporation , up to _______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not oth...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: _______ Initial Exercise Date: __, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used an...",
"Staten Island, New York 10305",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of May 16, 2023, and is between Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares, and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants and Common Warrant Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly...",
"Amendment to Existing Warrants",
"Investor Contact:" |
|
| 03/16/2023 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
8-K
| Quarterly results |
| 06/07/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Quarterly results |
| 11/16/2021 |
8-K
| Quarterly results|
Docs:
|
"ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 OPERATING EXPENSES Research and Development $ 1,126,972 $ 659,977 $ 1,313,954 $ 1,745,446 General and Administrative 3,515,250 654,569 8,873,160 1,761,561 TOTAL OPERATING EXPENSES 4,642,222 1,314,546 10,187,114 3,507,007 Gain on forgiveness of Paycheck Protection Program Loan — — 66,503 — NET LOSS $ $ $ $ LOSS PER SHARE Basic and diluted net loss per common share/units $ $ $ $ Weighted average pro forma shares outstanding basic and diluted 10,116,403 6,266,584 7,988,563 6,037,254 ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS" |
|
| 08/16/2021 |
8-K
| Quarterly results|
Docs:
|
"ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS June 30, December 31, 2021 2020 ASSETS CURRENT ASSETS Cash $ 17,095,596 $ 3,175,411 Prepaid Expenses 344,549 48,609 TOTAL ASSETS $ 17,440,145 $ 3,224,020 LIABILITIES AND MEMBERS' AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Accounts Payable and Accrued Expenses $ 1,918,639 $ 455,931 Paycheck Protection Program Loan - 16,625 TOTAL CURRENT LIABILITIES 1,918,639 472,556 NONCURRENT LIABILITIES Paycheck Protection Program Loan - 49,878 TOTAL LIABILITIES 1,918,639 522,434 COMMITMENTS AND CONTINGENCIES MEMBERS' AND SHAREHOLDERS' EQUITY Members' Equity, Class A - 16,402,198 Members' Equity, Class B - 100,000 Common Stock; $.001 par value, 200,000,000 shares authorized, 9,916,208 shares issued and outstanding at June 30, 2021 9,916 - Addi..." |
|
| 06/29/2021 |
8-K
| Quarterly results |
|
|